gdc-0134
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 31, 2016 (NCT02655614)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Death-associated protein kinase 3INHIBITOR
DAPK3 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Nc1ncc(-c2cc(N3C[C@@H]4C[C@H]3CO4)nc(N3CCC(F)(F)C3)n2)cc1OC(F)F- Mol. weight
- 440.4 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3732012 ↗
Also known as
- gdc-0134
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03807739 | Phase 1 | Feb 1, 2019 | Genentech, Roche |
| NCT03237741 | Phase 1 | Aug 7, 2017 | Genentech, Quotient, Roche |
| NCT02655614 | Phase 1 | May 31, 2016 | Genentech, Roche |
Showing 3 of 3 trials
Page 1 / 1